Most small pharma founders don't know what a DSUR is until FDA asks why they haven't filed one

If you are leading a small pharma or biotech startup, you might not have heard of a DSUR until the FDA asks why you haven’t filed one. This is a common situation. The Development Safety Update Report (DSUR) is an annual requirement for every active Investigational New Drug (IND) application. It’s not optional. It’s not something you file when you feel like it. The FDA expects it within 60 days of your IND anniversary date — every year, for as long as your IND is active.

Missing this deadline is more than a paperwork problem. It creates a compliance gap that the FDA can and does scrutinize, especially if something goes wrong in your trial. In this post, I’ll explain what a DSUR is, why it matters, what goes into it, and how you can avoid falling behind. I’ll also share practical tips to build DSUR compliance into your IND launch calendar from day one.

Eye-level view of a clinical trial document with a pen on a desk

DSUR report document on desk, ready for review

What is a DSUR and why does it matter?

A DSUR is a comprehensive safety report that summarizes all clinical and non-clinical safety information collected during the reporting period of your IND. It includes:

• A summary of subject exposure in your clinical trials

• Any significant safety findings or adverse events

• An assessment of whether the benefit-risk profile of your drug has changed

  
  

The FDA requires this report annually to monitor ongoing safety during drug development. It helps the agency identify potential risks early and ensures sponsors maintain safety oversight.

For small pharma founders, the DSUR often flies under the radar. You’re focused on science, fundraising, and getting your first patients enrolled. Regulatory filings like the DSUR can seem like a distant concern. But the FDA does not see it that way. They expect you to file the DSUR within 60 days of your IND anniversary date every year. Missing this deadline can trigger questions, delays, or even clinical holds.

What goes into a DSUR

The DSUR is not just a formality. It requires a clear, concise summary of safety data collected during the reporting period. Here’s what you need to include:

• Clinical safety data: All adverse events, serious adverse events, and any new safety signals from your clinical trials.

• Non-clinical safety data: Relevant toxicology or pharmacology findings from animal studies or other preclinical work.

• Subject exposure: A detailed analysis of how many subjects have been exposed to the drug, including dose levels and duration.

• Safety findings: Any significant new safety information that could affect the risk profile.

• Benefit-risk assessment: Your evaluation of whether the benefits of the drug still outweigh the risks based on the data collected.

  
  

This report is a snapshot of your drug’s safety profile at a given point in time. It helps the FDA track changes and decide if additional actions are needed.

Close-up view of a calendar with a marked IND anniversary date

Calendar showing IND anniversary date marked for DSUR filing

Why early-stage companies struggle with DSUR compliance

Many early-stage companies don’t realize the DSUR is an annual requirement until the FDA flags a missed deadline. By then, you may already be two filing cycles behind. This is not just a paperwork issue. It creates a compliance gap that can raise red flags during FDA inspections or if safety concerns arise in your trial.

Here are some common reasons why small pharma founders miss DSUR deadlines:

• Lack of regulatory expertise: Founders often come from scientific backgrounds and may not be familiar with regulatory timelines.

• No dedicated regulatory lead: Small teams may not have someone assigned to track and manage regulatory filings.

• Overwhelmed by other priorities: Fundraising, trial startup, and data collection take precedence over annual reports.

• No system for reminders: Without a calendar or process, the DSUR deadline can sneak up unnoticed.

  
  

Missing DSUR deadlines can lead to FDA questions, increased scrutiny, or even clinical holds. It also undermines investor confidence and can slow your drug development timeline.

How to avoid DSUR compliance gaps

The fix is straightforward but requires planning and discipline. Here’s what you should do before enrolling your first patient:

• Build the DSUR filing date into your IND launch calendar. Mark the IND anniversary date and set reminders at least 90 days in advance.

• Assign an owner. Designate a team member responsible for preparing and submitting the DSUR.

• Start early. Begin collecting safety data and drafting the report well before the deadline.

• Use tools or services to help. Consider regulatory consulting firms that specialize in IND lifecycle management to support your DSUR process.

  
  

For example, ClinReg Partners offers fractional regulatory support tailored for early-stage biotech companies. They help build regulatory calendars, prepare DSURs, and ensure you never miss a filing deadline. This kind of partnership can fill the gap if you don’t have in-house regulatory leadership.

Practical tips for DSUR preparation

Preparing a DSUR can feel overwhelming if you’re new to it. Here are some practical tips to make it manageable:

• Keep safety data organized from day one. Use a centralized system to track adverse events and clinical data.

• Review your IND annually. Use the DSUR preparation as an opportunity to review your entire safety profile.

• Collaborate with your clinical and safety teams. Make sure everyone understands what data is needed.

• Follow FDA guidance closely. The FDA provides detailed instructions on DSUR content and format.

• Plan for updates. If new safety signals emerge, update your DSUR accordingly.

  
  

By integrating DSUR preparation into your regular clinical operations, you reduce last-minute stress and improve report quality.

High angle view of a team meeting discussing clinical trial safety data

Team reviewing clinical safety data for DSUR preparation

Why regulatory compliance doesn’t grade on a curve

Regulatory compliance is a baseline expectation, not a bonus if you have time. The FDA expects annual filings on time, every time. Missing deadlines can lead to:

• Increased FDA scrutiny

• Delays in your clinical program

• Potential clinical holds

• Loss of investor confidence

  
  

You can’t afford to treat DSURs as optional or secondary. They are a critical part of your drug development program and your relationship with the FDA.

Summary and next steps

If you haven’t filed a DSUR yet, don’t wait for the FDA to ask why. Build your DSUR filing date into your IND calendar now. Assign a responsible owner and set reminders at least 90 days before the deadline. Start collecting and organizing safety data early. Consider partnering with regulatory experts who understand the FDA’s expectations and can help you stay compliant.

Remember, the DSUR is not just paperwork. It’s a safety check that protects your patients, your program, and your company’s future. Don’t let it sneak up on you.

If you want to learn more about how to manage your IND lifecycle and DSUR filings, consider consulting with firms like ClinReg Partners. They specialize in helping early-stage biotech companies navigate these regulatory challenges with confidence.

This post is for informational purposes only and does not constitute regulatory advice. Always consult with a qualified regulatory professional for your specific situation.